Improved tolerability of ritonavir derived from pharmacokinetic principles

A short term study of ing the administration of ritonavir 300 mg 6 hourly and the safety, pharmacokinetics and efficacy of ritonavir, an 600 mg 12 hourly (Figure 1 ).The reduced peak plasma inhibitor of HIV-1 protease.N Engl J Med 1995; 333: concentration following 6 hourly dosing may explain 1528-1533.the improved tolerance of ritonavir in our two patients 4 Moyle G, Gazzard B. Current knowledge and future despite taking the same total daily dose of 1200 mg.In prospects for the use of HIV protease inhibitors.Drugs addition, the trough levels expected with ritonavir 1996; 51: 701-712.300 mg 6 hourly do not fall below the 2.1 mg ml-1